• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts

    5/20/25 12:24:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email

    Both decisions benefited plaintiffs harmed by using Johnson & Johnson's Baby Powder

    National plaintiffs firm Dean Omar Branham Shirley, LLP, has been recognized by ALM and Law.com for securing two of the largest jury verdicts of 2024.

    Both cases involved claims against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) over its talc-based Baby Powder, which exposed users to asbestos, a known carcinogen.

    The 29th-ranked case on the ALM list was a $260 million verdict in Oregon on behalf of Kyung Lee, a 49-year-old mother of three who was diagnosed with mesothelioma after lifelong use of J&J's Baby Powder. Jurors awarded $60 million in compensatory damages and $200 million in punitive damages after finding that Johnson & Johnson knowingly sold asbestos-contaminated products.

    The firm also recorded the 82nd-ranked verdict, a $63 million judgment awarded in South Carolina to Michael Perry, a longtime hospitality professional diagnosed with terminal mesothelioma also linked to Johnson & Johnson's talc powder. The jury awarded $32.6 million in compensatory damages and $30.7 million in punitive damages.

    "These cases reflect the power of the jury system and the importance of holding even the most powerful corporations accountable," said Trey Branham, a partner at Dean Omar Branham Shirley. "Our clients showed incredible strength in telling their stories, and we're honored to have helped secure justice for them."

    Compiled by Law.com's VerdictSearch analysts, the 2024 Top 100 Verdicts list ranks the year's largest jury awards by gross amount. Touted as the most comprehensive roundup of top jury awards nationwide, the list highlights the year's most significant courtroom wins across the country.

    View the full list here.

    The cases listed are Kyung H. Lee et al. v. Bi-Mart Corporation et al., No. 23-CV-40369 in the Circuit Court of the State of Oregon for the County of Multnomah and Michael Perry v. American International Industries, et al., case number 2023-CP-40-04072 in South Carolina's 5th Judicial Circuit Court.

    About Dean Omar Branham Shirley, LLP

    Dean Omar Branham Shirley, LLP, is a nationally recognized trial firm that handles cases across the country for individuals who have suffered catastrophic injuries or have died as a result of the irresponsible conduct of others. For more information, visit http://www.dobslegal.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250520223599/en/

    Media Contact:

    BeLynn Hollers

    800-559-4534

    [email protected]

    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    12/1/2023$167.00 → $180.00Neutral → Buy
    UBS
    More analyst ratings

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Johnson & Johnson with a new price target

      Wolfe Research initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $190.00

      11/15/24 8:10:35 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

      Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose  MILAN, June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell therapy.1 Findin

      6/13/25 11:00:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

      TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study More than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24 Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced findings from the Phase 3b APEX study showing that TREMFYA® (guselkumab) significantly reduced both signs and symptoms of active psoriatic arthritis (PsA) and inhibited progression of joint structural damage at 24 w

      6/11/25 8:05:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

      Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

      6/10/25 4:51:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care